Gary W. Pace

Gary Pace has been a director since 2020. He has been a director of Pacira Biosciences, Inc. since 2008, Simavita Ltd. since 2016 and Antisense Therapeutics since 2015 as well as a director of several private companies. Dr. Pace previously served on the board of ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016 and ORxPharma Ltd. from 2001 to 2013. He is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He as co-founded several early-stage life science companies, where he built products from the laboratory to commercialization. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. The Board believes that Dr. Pace’s years of experience providing strategic advisory services to complex organizations, including as a public company director provides him with the qualifications and skills to serve as a director.